A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy

Trial Profile

A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs Abiraterone acetate (Primary) ; Dexamethasone
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cougar Biotechnology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 May 2009 Actual patient number (44) added as reported by ClinicalTrials.gov.
    • 03 Jun 2008 Interim results presented at the American Society of Clinical Oncology (ASCO) 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top